July 14

Cardiome Announces Positive Phase 2b Results For Oral Vernakalant

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced positive clinical results from its 90-day Phase 2b study of vernakalant (oral). The final analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data from the final analysis also shows that vernakalant (oral) was well-tolerated in the atrial fibrillation population studied.

The final results demonstrated that the 500mg dosing group significantly reduced the rate of atrial fibrillation relapse as compared to placebo (two-sided log rank, p=0.0221). The median time to recurrence of atrial fibrillation was greater than 90 days for the 500mg dosing group, compared to 27 days for the placebo group, an even stronger signal of sinus rhythm maintenance than what was seen in the interim analysis.
Read more: Cardiome Pharma Corp ( COM )
July 14

First Quantum Minerals Reports New Quarterly Record Copper Production in Second Quarter 2008

First Quantum Minerals Ltd. (\"First Quantum\" or the \"Company\") (TSX: FM)(LSE: FQM) today announced a new quarterly record copper production of 80,600 tonnes for the second quarter of 2008. The new record exceeds the production levels of the second quarter of 2007 and the first quarter of 2008 by over 60% and 6%, respectively.
Read more: First Quantum Minerals Ltd ( FM )
July 14th

Osisko Intersects 178 Metres Averaging 2.44 g/t Gold at South Barnat

Osisko Mining Corp. (TSX: OSK)(FRANKFURT: EWX) is pleased to announce new results from the definition drill program currently under way on the South Barnat Zone, a separate gold mineralized zone located approximately 1200 metres northeast of the center of the Canadian Malartic deposit. Significant new results include 2.44 g/t Au over 178.0 metres (BA08-3008) and 3.38 g/t Au over 85.0 metres in hole BA08-3016. Results from twelve new holes are tabled below:
Read more: Osisko Mining Corp ( OSK )
July 14

Gammon Gold Confirms the Third Consecutive Quarter of Improvements in Several Key Performance Indicators with a 23% increase in Production & a 59% increase in Operating Cash Flow over Q1 2008

Gammon Gold Inc. (\"Gammon\") (TSX:GAM and AMEX:GRS): Gammon confirmed today that Q2 2008 production and cash flow performance has successfully built on the strong results achieved in Q1 2008 and is reporting another consecutive quarter of best ever production and operating cash flow in the history of the company. The strong production continues to drive positive cash flow performance and the strength of the operating cash flow continues to fund 100% of the expansion capital and the new aggressive exploration program. This has positioned the company such that it has not made a draw down on its debt facility in over 6 months and the Company has made $8.0 million in unscheduled repayments including an additional $0.9 million repayment in early July.

\"The turnaround strategy launched in December 2007 had an initial focus on improving productivity and that strategy has had an obvious and positive impact on production that has exceeded even our internal targets to date.
Read more: Gammon Gold Inc ( GAM )
July 14th

ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))

ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, today said it has received authorization from the FDA to begin marketing its MarrowXpress (MXP) device for use in a clinical laboratory setting or intraoperatively for preparation of a cell concentrate from bone marrow.

Last month, the Company announced it had submitted a 510(k) pre-market notification application to the FDA. Upon its review, the FDA determined that the device was exempt from the agency\'s pre-market notification requirements and will instead be regulated as laboratory equipment labeled for a specific medical use. The device is a derivative of the Company\'s AutoXpress(TM) (AXP(TM)) Platform that is used to volume reduce and collect stem cells from umbilical cord blood.
Read more: ThermoGenesis Corp ( KOOL )